Collegium to Showcase Real-World Pain Data at PainConnect 2026
Event summary
- Collegium Pharmaceutical will present two posters featuring real-world data from its pain portfolio at PainConnect 2026, taking place in Salt Lake City from March 5-8, 2026.
- The presentations will focus on the real-world clinical insights of BELBUCA®, Collegium’s differentiated pain medication.
- The poster presentations will take place on Friday, March 6, at The Grand America Hotel.
- The abstracts will cover the rate and frequency of nonmedical use of buprenorphine compared to other opioids and the presence of illicit drugs in urine drug testing among pain clinic patients.
The big picture
Collegium’s presentation at PainConnect 2026 underscores the growing emphasis on real-world evidence in the pain management sector. As the industry grapples with the balance between effective pain relief and the risks of opioid misuse, Collegium’s data could provide valuable insights. The strategic focus on generating evidence that informs everyday practice aligns with broader trends in pharmaceutical research and development, where real-world data is increasingly seen as critical for optimizing treatment outcomes.
What we're watching
- Data Impact
- How the real-world data will influence clinical practice and scientific dialogue in pain management.
- Regulatory Scrutiny
- Whether the findings will attract regulatory attention given the risks associated with opioid use.
- Market Positioning
- The pace at which Collegium can leverage this data to strengthen its position in the pain management market.
Related topics